Inhaled corticosteroids and long-acting β2-agonists in treatment of patients with chronic bronchiolitis following exposure to sulfur mustard

Inhalation Toxicology

Volumn 19, Issue 10, 2007, Pages 889-894

  Ghanei, Mostafa ^a   Shohrati, Majid ^a   Harandi, Ali Amini ^a   Eshraghi, Mehdi ^a   Aslani, Jafar ^a   Alaeddini, Farshid ^a   Manzoori, Hasan ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; MUSTARD GAS; SALBUTAMOL;

ARTICLE; BRONCHIOLITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG WITHDRAWAL; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CIRCULATION; LUNG FUNCTION TEST; PATIENT ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; BRONCHIOLITIS; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INHALATION EXPOSURE; MALE; MIDDLE AGED; MUSTARD GAS; RECEPTORS, ADRENERGIC, BETA-2;

EID: 34547813195     PISSN: 08958378     EISSN: 10917691     Source Type: Journal    
DOI: 10.1080/08958370701432132     Document Type: Article

References (18)

1. American Thoracic Society. 1979. Standardization of spirometry. Am. Rev. Respir. Dis. 119:831-838.
2. Beheshti, J., Mark, E. J., Akbaei, H. M., Aslani, J., and Ghanei, M. 2006. Mustard lung secrets: Long term clinicopathological study following mustard gas exposure. Pathol. Res. Pract. 202:739-744.
3. Chacon, R. A., Corris, P. A, Dark, J. H, and Gibson, G. J. 2000. Tests of airway function in detecting and monitoring treatment of obliterative bronchiolitis after lung transplantation. J. Heart Lung Transplant. 19(3):263-269.
4. Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., and Maden, C. 2003. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 361(9356):449-456.
5. Dransfield, M. T., and Bailey, W. C. 2004. Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease. Expert Opin. Pharmacother. 5(8):1815-1826.
6. Ezri, T., Kunichezky, S., Eliraz, A., Soroker, D., Halperin, D., and Schattner, A. 1994. Bronchiolitis obliterans - Current concepts. Q. J. Med. 87(1):1-10.
7. Fenton, C., and Keating, G. M. 2004. Inhaled salmeterol/fluticasone propionate: A review of its use in chronic obstructive pulmonary disease. Drugs 64(17):1975-1996.
8. Fullmer, J., Fan, L., and Dishop, M. 2005. Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-blockade. Pediatrics 116(3):767-770.
9. Ghanei, M., Khalili, A. R., Arab, M. J., Mojtahedzadeh, M., Aslani, J., Lessan-Pezeshki, M., Panahi, Y., and Alaeddini, F. 2005. Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbation of mustard gas-induced chronic bronchitis. Basic Clin. Pharmacol. Toxicol. 97(5):302-305.
10. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2001. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report, NIH publication 2701. Bethesda, MD: U.S. Department of Health and Human Services.
11. Martin, R. J., Szefler, S. J., Chinchilli, V. M, Kraft, M., Dolovich, M., Boushey, H. A., Cherniack, R. M., Craig, T. J., Drazen, J. M., Fagan, J. K., Fahy, J. V., Fish, J. E., Ford, J. G., Israel, E., Kunselman, S. J., Lazarus, S. C., Lemanske, R. F., Jr., Peters, S. P., and Sorkness, C. A. 2002. Systemic effect comparisons of six inhaled corticosteroid preparations. Am. J. Respir. Crit. Care Med. 165:1377-1383.
12. Mason, R. J. 2005. Murray&Nadel's textbook of respiratory medicine, 4th ed. Philadelphia: Saunders.
13. Mirsadraee, M., Attaran, D., Boskabady, M. H., and Towhidi, M. 2005. Airway hyperresponsiveness to methacholine in chemical warfare victims. Respiration 72(5):523-528.
14. O'Brien, A., Russo-Magno, P., Karki, A., Hiranniramol, S., Hardin, M., Kaszuba, M., Sherman, C., and Rounds, S. 2001. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am. J. Respir. Crit. Care Med. 64(3):365-371.
15. Perrin-Fayolle, M. 1995. Bronchiolitis obliterans in adults. Presse Med. 18;24(7):362-365.
16. Shrewsbury, S., Pyke, S., and Britton, M. 2000. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br. Med. J. 320(7246):1368-1373.
17. Soriano, J. B., Vestbo, J., Pride, N. B., Kiri, V., Maden, C., and Maier, W. C. 2002. Survival in COPD patients after regular use of fluticasone propionate and salmetrol in general practice. Eur. Respir. J. 20(4):819-825.
18. Wong, J. Y., Moon, S., Beardsmore, C., O'Callaghan, C., and Simpson, H. 2000. No objective benefit from steroids inhaled via a spacer in infants recovering from bronchiolitis. Eur. Respir. J. 15(2):388-394.